The Claim
The selective CaMKK2 inhibitor SGC-CAMKK2-1 inhibits glucose uptake in mouse skeletal muscle independently of CaMKK2, as it also blocks glucose uptake stimulated by insulin and AMPK activators, and its inactive analog produces the same effect.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
SGC-CAMKK2-1 reduces glucose uptake in mouse skeletal muscle regardless of whether the uptake is triggered by insulin or AMPK activators, and an inactive version of the compound has the same effect.
See the scientific wording
The selective CaMKK2 inhibitor SGC-CAMKK2-1 inhibits glucose uptake in mouse skeletal muscle independently of CaMKK2, as it also blocks glucose uptake stimulated by insulin and AMPK activators, and its inactive analog produces the same effect.
A drug designed to block CaMKK2 stops muscle cells from taking in sugar, but not because it touches CaMKK2. The drug and even a version that can't block CaMKK2 both block sugar uptake by directly interfering with the proteins that move glucose into the cell, regardless of whether insulin or energy stress is triggering the uptake.
What the research says
1 studyThe drug was supposed to block a protein called CaMKK2, but it still stopped muscle cells from taking up sugar even when that protein was missing or when a fake version of the drug was used — meaning the drug is messing with something else entirely.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.